Premium
Novel antibodies targeting immune regulatory checkpoints for cancer therapy
Author(s) -
Lee Chern Siang,
Cragg Mark,
Glennie Martin,
Johnson Peter
Publication year - 2013
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.12164
Subject(s) - immune system , monoclonal antibody , immunotherapy , antibody , cancer , cancer immunotherapy , melanoma , immunology , immune checkpoint , cancer research , medicine , computational biology , biology
Cancers must evade or suppress the immune system in order to develop. Better understanding of the molecular regulation governing tumour detection and effective activation of the immune system (so called immune regulatory checkpoints) has provided new targets for cancer immunotherapy. Therapeutic monoclonal antibodies against these targets are currently undergoing clinical evaluation with more in pre‐clinical development; buoyed by the recent licence approval of the anti‐ CTLA ‐4 antibody, ipilumumab, for use in melanoma. This article will review the current status of the various antibodies and target molecules being investigated.